Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase
Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021
Full Year 2023 Total Revenues are Expected to be $210 Million or More, Representing Approximately 40% Year-Over-Year Growth Rate
First-Time Positive EBITDA Expected During Second Half of 2023
https://finance.yahoo.com/news/adma-biologics-announces-preliminary-fourth-120000794.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.